What is Curesponse?
Headquartered in Rehovot, Israel, Curesponse operates at the intersection of biotechnology and data science. The company has developed the cResponse platform, a sophisticated diagnostic tool designed to predict individual patient responses to specific cancer treatments with high accuracy and speed. By moving beyond the one-size-fits-all approach to oncology, Curesponse provides clinicians with actionable insights that optimize therapeutic efficacy and minimize unnecessary patient exposure to ineffective regimens. The company's market position is defined by its ability to bridge the gap between complex genomic data and clinical decision-making, effectively serving as a critical partner for healthcare providers and pharmaceutical developers alike.
How much funding has Curesponse raised?
Curesponse has raised a total of $14M across 2 funding rounds:
Series A
$6M
Unspecified
$8M
Series A (2020): $6M with participation from aMoon and NCL Technology Ventures Ltd
Unspecified (2021): $8M, investors not publicly disclosed
Key Investors in Curesponse
aMoon
A prominent health-tech and life sciences venture capital firm that focuses on accelerating the growth of companies transforming the future of healthcare.
NCL Technology Ventures Ltd
An investment entity specializing in the support of innovative technology-driven enterprises with high growth potential in the life sciences and industrial sectors.
Undisclosed Investor
An undisclosed institutional participant providing strategic backing to support the company's ongoing clinical and commercial development initiatives.
What's next for Curesponse?
With the recent influx of capital, Curesponse is expected to prioritize the scaling of its cResponse platform across international clinical settings. The strategic roadmap likely involves deepening partnerships with major oncology centers to integrate its predictive analytics into standard care protocols. Furthermore, the company is poised to invest in further research and development to broaden the scope of its diagnostic platform, potentially addressing a wider array of solid tumors. As the firm transitions from its current growth phase toward broader commercialization, the focus will remain on demonstrating long-term clinical utility and securing regulatory milestones that validate its role as a leader in the personalized medicine sector.
See full Curesponse company page
